Kristina Burow


Ms. Burow has served as a member of our board of directors since May 2015. She has served as Managing Director of ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. She currently serves on the board of several biopharmaceutical and biotechnology companies, including Scholar Rock Holding Corporation, Vividion, Beam Therapeutics, Lycera Corp., BlackThorn Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Unity Biotechnology, Inc., AgBiome Inc., Vir Biotechnology Inc. and Gossamer Bio, Inc. Ms. Burow previously was a co-founder and member of the board of directors of Receptos Inc., until its acquisition by Celgene Corporation, and of Sapphire Energy, Inc., an energy company. She has participated in a number of other ARCH portfolio companies including KYTHERA, Siluria Technologies, Inc., an energy company, and Ikaria, Inc., a biotechnology company, acquired by Madison Dearborn Partners. Prior to joining ARCH, Ms. Burow was an associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. She received a B.A. in chemistry from the University of California, Berkeley, an M.A. in chemistry from Columbia University, and an MBA from the University of Chicago.